Anika Therapeutics, Inc.ANIKNASDAQ
Loading
R&D Expenses Over TimeStrong
Percentile Rank93
3Y CAGR+12.0%
5Y CAGR+1.9%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+12.0%/yr
vs +0.2%/yr prior
5Y CAGR
+1.9%/yr
Recent acceleration
Acceleration
+11.9pp
Accelerating
Percentile
P93
Near historical high
vs 5Y Ago
1.1x
Modest growth
Streak
3 yr
Consecutive growthStrong
PeriodValueYoY Change
TTM$25.77M+0.9%
2024$25.54M+17.4%
2023$21.76M+18.8%
2022$18.32M-33.0%
2021$27.33M+16.6%
2020$23.43M+40.6%
2019$16.66M-8.4%
2018$18.19M-3.2%
2017$18.79M+75.1%
2016$10.73M-